Companies › Estar Medical dba Medical Technologies
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tropocells(R) Autologous Platelet-Rich Fibrin (PRF) Autologous platelet-rich fibrin for wound healing | – | Phase 2 | Diabetic Foot Ulcer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06810726 | Tropocells(R) Autologous Platelet-Rich Fibrin (PRF) | Phase 2 | Diabetic Foot Ulcer | Metabolic and endocrine | May 2026 |
No annotated target.
–
Wellizen Australia AB Biotics Immunis Spur Therapeutics iECURE
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.